F-box protein 39Genealiases: CT144 · FBOX39 · Fbx39
Q-omics provides the consensus-scored FBXO39 profile across patient tissues and cancer cell-line models. FBXO39 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FBXO39 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, FBXO39 RNA expression shows 15,199 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where FBXO39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO39 survival associations across molecular data types. FBXO39 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO39 RNA expression–survival associations across cancer types. High FBXO39 expression shows unfavorable associations in KIRP, LGG, KIRC and UVM, but favorable associations in SKCM and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FBXO39 RNA expression.
This table summarizes FBXO39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FBXO39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO39 shows lower tumor expression in UCEC and KIRP and higher tumor expression in HNSC, KIRC, COAD and LIHC. The HNSC box plot shows higher FBXO39 RNA expression in tumor versus normal tissue (log2 FC = +0.625, t-test p < 0.001).
This table shows molecular features associated with FBXO39 in patient tissues and cancer cell lines. In patient samples, FBXO39 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
